Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2024-08-12 13:00:00
According to the announcement made on the 2nd of July 2024, a majority of the
shareholders have confirmed interest in replacing today's ECOB Geir Hermod Almås
with Ulrik Spork. The new board is expected to replace today's ICEO Christian
Harstad with Thomas Bjarnsholt. To facilitate this Geir Hermod Almås and
Christian Harstad have agreed to step down from their positions by early
September 2024.
ECOB Geir Almås has agreed to step down from his position after completing the
ongoing Right Issue. While being ECOB Geir Almås has been on leave from his
position as Chief Executive Officer of Business Development. He has also had a
consultancy agreement regulating his role as ECOB. These contracts give him 12
months' salary after pay. Geir Almås has agreed to cancel all existing contracts
with the company and has accepted a six-month salary paid as shares with a total
amount of 58.326.042 shares. The amount is calculated based on a six-month
salary and the theoretical ex-right price (TERP) of NOK 0,0226 per share.
ICEO Christian Harstad has accepted negotiated terms for the cancellation of his
employment contract with SoftOx Solutions AS which originally would have
entitled him to receive 12 months after payment. Christian Harstad has accepted
to receive only 3 months where two months will be compensated in cash and one
month will be compensated with shares. The number of shares is calculated by
using implicit theoretical ex-right price after the ongoing right issue is
closed (TERP) equal to NOK 0,0226 per share.
For further information, please contact:
Ingrid Juven, CFO of SoftOx Solutions AS
e-mail: ir@soft-ox.com
Phone: Ingrid Juven, CFO: (+47) 918 76 165
About SoftOx Solutions AS:
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a
Norwegian MedTech/biotech company based in Oslo with the aim of helping to
combat major threats to human health, namely the emergence of antimicrobial
resistance (AMR), biofilm infections in chronic wounds and the spread of
viruses.
For more information on SoftOx, visit www.soft-ox.com